TRPC3 contributes to regulation of cardiac contractility and arrhythmogenesis by dynamic interaction with NCX1

Bernhard Doleschal1, Uwe Primessnig2,3, Gerald Wölkart1, Stefan Wolf1, Michaela Schernthaner4, Michaela Lichtenegger1, Tomáš N. Glasnov5,6, C. Oliver Kappe5, Bernd Mayer1, Gudrun Antoons2,3, Frank Heinzel2,3, Michael Poteser4, and Klaus Groschner3,4*

1Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria; 2Department of Cardiology, Medical University of Graz, Graz, Austria; 3Ludwig Boltzmann Institute of Translational Heart Failure Research, Graz, Austria; 4Institute of Biophysics, Medical University of Graz, Harrachgasse 21, Graz 8010, Austria; 5Institute of Chemistry, University of Graz, Graz, Austria; and 6Christian Doppler Laboratory for Continuous Flow Chemistry, Institute of Chemistry, University of Graz, Graz, Austria

Received 17 October 2014; revised 17 December 2014; accepted 19 January 2015; online publish-ahead-of-print 28 January 2015

Time for primary review: 31 days

Aim
TRPC3 is a non-selective cation channel, which forms a Ca2+ entry pathway involved in cardiac remodelling. Our aim was to analyse acute electrophysiological and contractile consequences of TRPC3 activation in the heart.

Methods and results
We used a murine model of cardiac TRPC3 overexpression and a novel TRPC3 agonist, GSK1702934A, to uncover (patho)physiological functions of TRPC3. GSK1702934A induced a transient, non-selective conductance and prolonged action potentials in TRPC3-overexpressing myocytes but lacked significant electrophysiological effects in wild-type myocytes. GSK1702934A transiently enhanced contractility and evoked arrhythmias in isolated Langendorff hearts from TRPC3-overexpressing but not wild-type mice. Interestingly, pro-arrhythmic effects outlasted TRPC3 current activation, were prevented by enhanced intracellular Ca2+ buffering, and suppressed by the NCX inhibitor 3′,4′-dichlorobenzamil hydrochloride. GSK1702934A substantially promoted NCX currents in TRPC3-overexpressing myocytes. The TRPC3-dependent electrophysiologic, pro-arrhythmic, and inotropic actions of GSK1702934A were mimicked by angiotensin II (AngII). Immunocytochemistry demonstrated colocalization of TRPC3 with NCX1 and disruption of local interaction upon channel activation by either GSK1702934A or AngII.

Conclusion
Cardiac TRPC3 mediates Ca2+ and Na+ entry in proximity of NCX1, thereby elevating cellular Ca2+ levels and contractility. Excessive activation of TRPC3 is associated with transient cellular Ca2+ overload, spatial uncoupling between TRPC3 and NCX1, and arrhythmogenesis. We propose TRPC3-NCX micro/nanodomain communication as determinant of cardiac contractility and susceptibility to arrhythmogenic stimuli.

Keywords
TRPC3 • NCX1 • Ca2+ handling • Cardiac contractility • Arrhythmias

1. Introduction
Hypertrophic remodelling of the myocardium is typically initiated by stimuli originating from either release of neuroendocrine factors such as angiotensin II (AngII),1 endotelin I.,2 noradrenalin3 or by exaggerated mechanical strain.4 These pathogenic stimuli trigger cellular Ca2+ signals that modify gene expression to restructure the myocardium. The pivotal signalling role of Ca2+ in cardiac remodelling is well established5,6 and involves spatial linkage between Ca2+ entry channels and Ca2+-dependent signalling molecules, such as calmodulin-dependent protein kinase II (CaMKII),7 PKC,8 and calcineurin (CaN).9,10 A critical step in the early stage of cardiac remodelling is up-regulation of the expression of certain Ca2+ channel proteins to modify cardiac Ca2+ homeostasis and Ca2+-transcription coupling. Some Ca2+ channels,
such as voltage-gated l-type channels (Ca\textsubscript{2+}L), are capable of serving both normal excitation–contraction as well as excitation–transcription coupling. In contrast, voltage-insensitive channels are considered to control preferentially Ca\textsubscript{2+} signals that activate gene transcription. Initiation of Ca\textsubscript{2+}-dependent processes of transcriptional regulation is likely to take place in specialized regulatory microdomains that are somehow segregated from the oscillatory rise and fall in cytoplasmic Ca\textsubscript{2+}, as associated with excitation–contraction coupling.

Voltage-in sensitive TRPC channels were found up-regulated in response to mechanical stress-associated afterload\textsuperscript{15 – 17} or increased neurohumoral stimuli.\textsuperscript{1,3,15,16} TRPC3 has been demonstrated to supply Ca\textsubscript{2+} in a highly efficient and selective manner for CaN regulation,\textsuperscript{4,12} which requires minute membrane currents and is not associated with global cytoplasmic Ca\textsubscript{2+L}. Nonetheless, non-selective cation conductances, as generated by TRPC channels, are expected to impact on excitability and contractile function of cardiomyocytes. Nonetheless, the consequences of acute activation of cardiac TRPC channels, especially in conditions of enhanced expression such as cardiac hypertrophy or heart failure, are so far unclear, and the role of non-selective cation conductances in cardiac dysfunction during remodelling is incompletely understood. Previous studies\textsuperscript{17 – 20} in neonatal and adult cardiac cells suggested negligible involvement of TRPC3 in excitation–contraction coupling. TRPC3 channel display only weak Ca\textsubscript{2+L} over Na\textsuperscript{+} permeability (Ca\textsubscript{2+L}/Na\textsuperscript{+} = 1.6) and a characteristic double-rectifying current to voltage feature, thus allowing for significant Na\textsuperscript{+} loading and depolarization during diastole. Hence, activation of this conductance is expected to generate significant disturbances in action potential morphology and to simultaneously shift equilibrium and operation of electrogenic Na\textsuperscript{+} transport specifically of NCX1, which has repeatedly been demonstrated as a signalling partner of TRPC channels in muscle cells.\textsuperscript{2,21,22} Analysis of acute functional consequences of TRPC3 is limited by its complex mechanism of activation, which typically involves stimulation of phospholipase C and thereby several routes linked to excitation–contraction coupling. Availability of a direct small molecule activator of TRPC3 (GSK1702934A) prompted experiments to identify the acute consequences of TRPC3 activation in a murine model of cardiac overexpression and to compare its functional effects with that of AngII, a classical mediator activating TRPC conductances. With this study, we demonstrate that TRPC3 is a determinant of cardiac contractility and excitability. This function of TRPC3 is based on its interaction with NCX1, which translates TRPC3 activity into altered cellular Ca\textsubscript{2+} handling and action potential morphology.

2. Methods

2.1 GSK synthesis

GSK1702934A\textsuperscript{1,23} was prepared according to the method illustrated in scheme 1.

![Scheme 1. Synthetic route to GSK1702934A. Reagents and conditions: (i) oxalyl chloride, DMF, DCM, 0°C to r.t., 1 h, 80%; (ii) 4-(2-keto-1-benzimidazolyl) piperidine, DMAP, DCM, 0°C to r.t., 15 min, 82%.

2.2 Transgenic animal model, functional and biochemical experiments

A transgenic mouse model of cardiac-specific TRPC3 overexpression (low expression line 23; TRPC3-TG), generated by Prof. Molkentin,\textsuperscript{9,10,17} was compared with age-matched (2–4 months) and sex-matched wild-type (WT) littermate controls (FVB/N strain). Langendorff-perfused whole hearts,\textsuperscript{24,25} electrophysiological recordings in single isolated myocytes, fluo-4 Ca\textsubscript{2+} imaging, western blots, immunocytochemistry, and confocal imaging were performed. Data were subjected to statistical analysis using KaleidaGraph 4.5 and Origin 6.1 software. All substances used were of the highest purity available. Experimental details are provided in an extended methods section in the Supplementary material online.

3. Results

3.1 Selective activation of a TRPC3 conductance in cardiomyocytes

A novel activator of lipid-sensitive TRPC channels, GSK1702934A (GSK), has recently been introduced.\textsuperscript{23} Availability of this compound by custom synthesis prompted us to investigate the acute functional consequences of TRPC3 activation in the heart and a scenario lacking phospholipase C stimulation and signalling pathways that hamper evaluation of the exact role of the channel. When challenged with GSK (1 μM), TRPC3-transgenic (TG) cardiomyocytes exhibited a non-selective membrane conductance with features resembling that of heterologously expressed TRPC3 channels. In contrast to control (WT) cardiomyocytes, TRPC3-TG cardiomyocytes displayed the typical double-rectifying characteristics of TRPC3 currents (Figure 1A) as previously described for the HEK293 overexpression system.\textsuperscript{2} GSK-induced membrane currents in TRPC3-overexpressing HEK293 cells are illustrated for comparison in Figure 1B.\textsuperscript{23} Time courses of GSK-sensitive currents were similar in TRPC3-TG cardiomyocytes (Figure 1A, lower panel) and transiently TRPC3-expressing HEK-293 cells (Figure 1B, lower panel). Peak currents were typically observed 10–15 s after application of the activator and declined to basal levels within 30 s. Current activation was not suppressed by elevation of the intracellular Ca\textsubscript{2+} concentration. The action potential duration (APD\textsubscript{90}) in TRPC3-overexpressing myocytes (Figure 1C, lower panel) was compared with age-matched (2–4 months) and sex-matched wild-type (WT, low expression line 23; TRPC3-TG), generated by Prof. Molkentin,\textsuperscript{9,10,17} using KaleidaGraph 4.5 and Origin 6.1 software. All substances used were of the highest purity available. Experimental details are provided in an extended methods section in the Supplementary material online.
TRPC3 current for electrical and mechanical function of murine hearts using the isolated perfused Langendorff preparation.

3.2 TRPC3 activity contributes to control of cardiac contractility and arrhythmogenesis

GSK (1 μM) lacked significant effects on contractility of isolated perfused hearts from WT mice, but it generated a clear positive inotropic response in TRPC3-TG hearts (Figure 2A and see Supplementary material online, Figure S3A). The positive inotropic response was transient with left ventricular systolic pressure reaching a peak (LVSP: 119.1 ± 5.2%; dP/dt: 122 ± 4%; P < 0.05; N = 8) ~3–4 min after start of GSK perfusion. In the majority of experiments, GSK initiated a rise in diastolic pressure, eventually leading to significant diastolic deterioration. Interestingly, we did not observe any differences in cardiac performance at baseline between WT and TRPC3-TG mouse hearts (WT, LVDevP (left ventricular developed pressure, LVSP-LVDP): 106.9 ± 1.8 mmHg vs. TRPC3-TG, LVDevP: 100.9 ± 6.9 mmHg; P > 0.1). Thus, we report here on a novel principle of positive inotropism based on TRPC3 activation. Similar to GSK, AngII initiated transient positive inotropic effects, which amounted to 110% in WT hearts (LVSP: 114.2 ± 1.1%; dP/dt: 108.5 ± 1.3%; P < 0.01; N = 10) and was exaggerated up to 140% in TRPC3-TG mouse hearts (LVSP: 137.2 ± 14.8%; dP/dt: 138.5 ± 7.2%; P < 0.01; N = 15). This positive inotropic effect was followed by a sudden cardiac dysfunction with increasing diastolic pressure and transient loss of function, from which the majority of hearts recovered spontaneously within 1 min (see Supplementary material online, Figure S4A). This suggests an involvement of TRPC3 in functional effects of AngII at elevated expression levels of TRPC3.

Detailed inspection of LVP twitch traces revealed a higher incidence of arrhythmic events in GSK-exposed hearts from TRPC3-TG (median level 2) compared with WT mice (median level 1; P < 0.1) (Figure 2B). WT as well as TRPC3-TG hearts displayed rare isolated arrhythmic events (ventricular or atrial premature beats) in non-stimulated (basal) conditions.
GSK exerted a significant pro-arrhythmic action in TRPC3-TG hearts (basal condition: median level 1 vs. median level 2 during GSK application; \( P < 0.05 \)), characterized by paired ventricular beats, burst of atrial tachycardia, and cardiac alternans in a majority of experiments. GSK in contrast failed to significantly enhance the burden of arrhythmic events in WT hearts as quantified by an arrhythmia scoring system (basal condition: median level 1 vs. median level 1 during GSK application; \( P = \text{NS} \)) (Figure 2B). In three out of eight TRPC3-TG hearts, short, transient episodes of ventricular tachycardia were induced by GSK (see Supplementary material online, Figure S3B). Similarly, LVP traces from TRPC3-overexpressing hearts revealed a transient burden of arrhythmic activity during AngII challenge. This was characterized by sustained episodes of bigeminal beats during the positive inotropic phase and episodes of atrial or ventricular tachycardia and ventricular or atrial premature beats during recovery of cardiac function (see Supplementary material online, Figure S4). The AngII-induced disturbance of cardiac rhythm increased to Levels 3–4 on the arrhythmia scoring for TRPC3-TG hearts (basal condition: median level 1 vs. median level 4 during GSK application; \( P < 0.01 \)), while WT hearts lacked significant rhythmical disturbances during AngII perfusion (basal condition: median level 1 vs. median level 2 during GSK application; \( P = \text{NS} \)) (see Supplementary material online, Figure S4A).

### 3.3 TRPC3 activity promotes arrhythmias by a mechanism involving cellular Ca\(^{2+}\) handling and NCX1

The arrhythmogenic action of GSK was clearly evident from AP recording in isolated myocytes. Analysis of 10 min continuous recordings during GSK perfusion revealed a higher incidence of arrhythmic depolarizations (early and late afterdepolarizations) in TRPC3-TG compared with WT cardiomyocytes (Figure 3A and 3B). It is of note that the effects of AngII in isolated TRPC3-TG cardiomyocytes resembled that of GSK in terms of changes in AP morphology (see Supplementary material online, Figure S4D).

Interestingly, when Ca\(^{2+}\) was efficiently buffered at diastolic levels by intracellular EGTA (11 mM), which did not prevent TRPC3 currents (Figure 1A), arrhythmic activity of GSK was blunted (Figure 3C) and prolongation of APD\(_{90}\) by GSK was barely detectable (see Supplementary material online, Figure S5). These results suggest that TRPC3-mediated
Arrhythmic events and changes in AP morphology are not simply a consequence of the TRPC conductance itself, but involve a more complex linkage between the TRPC conductance and cellular Ca\textsuperscript{2+} handling. As elevated Ca\textsuperscript{2+}i is a well-recognized trigger for NCX-mediated arrhythmic events\textsuperscript{28–30}, we hypothesized a role of distorted Ca\textsuperscript{2+} homeostasis and NCX1 function in GSK-induced initiation of arrhythmic events. Detailed analysis of arrhythmic activity revealed that a majority of afterdepolarizations occurred either after complete repolarization or at negative potentials more negative than \(-250\) mV during repolarization (see Supplementary material online, Figure 6) and may therefore well be based on NCX-mediated inward currents.\textsuperscript{31} Preincubation of TRPC3-TG cardiomyocytes with 10 \(\mu\)M 3′,4′-dichlorobenzamil hydrochloride (DCB), a pharmacological tool to inhibit NCX forward-mode activity,\textsuperscript{32} indeed markedly reduced the number of arrhythmic events evoked by GSK, pointing towards TRPC3-triggered alteration of NCX1 function as the basis of the pro-arrhythmic action of GSK (Figure 3). NCX1 expression was found unchanged in TRPC3-TG and WT cardiomyocytes (see Supplementary material online, Figure S7), substantiating a functional link between TRPC3 and NCX1. Signalling crosstalk based on micro/nanodomain organization of the channel in proximity of the transporter has already been demonstrated for cardiovascular cells.\textsuperscript{22,33} We hypothesized that TRPC3 activation may promote NCX operation during action potentials.

Initial characterization of the effects of AngII on NCX1 forward-mode activity by tail current analysis revealed that AngII increased NCX-inward currents only in TRPC-TG myocytes (see Supplementary material online, Figure S2C). To test whether TRPC3 expression and activity indeed determines exchanger operation during cyclic de- and repolarization, we performed patch-clamp experiments in TRPC3-TG cardiomyocytes to delineate cyclic NCX function as the Ni\textsuperscript{2+}-sensitive current component (Figure 4). These experiments were performed in the absence of functional sarcoplasmic reticulum (SR) using a voltage-clamp protocol to quantify reverse- and forward-mode NCX activity during depolarization and subsequent repolarization, respectively.\textsuperscript{34,35} SR function was disrupted with thapsigargin (Tg, 3 \(\mu\)mol/L), and voltage-gated Ca\textsuperscript{2+} entry was blocked with nitrendipine (10 \(\mu\)M). TRPC3-TG myocytes displayed elevated NCX outward as well as consecutive inward currents compared with wild-type myocytes when applying strong depolarizing voltage steps (+100 mV; Figure 4). Moreover, NCX currents were significantly amplified by TRPC3 overexpression

Figure 3 Arrhythmic activity in cardiomyocytes in response to TRPC3 activation requires rise of intracellular Ca\textsuperscript{2+} and NCX1 function. Action potentials were recorded from single myocytes upon intracellular current injection (1–2 nA amplitude, 2–4 ms duration) at a pacing cycle length of 2 s.\textsuperscript{28} (A) Continuous AP recordings displayed prominent arrhythmic afterdepolarizations (EADs and DADs) in TRPC3-TG myocytes during GSK infusion; WT (left panel), TRPC3-TG (right panel). (B) Frequency of arrhythmic events (number of EADs and DADs during 10 min application of GSK). Both EADs (4.7 \(\pm\) 1.79 TG; \(n = 15\); \(N = 3\)) or 0.3 \(\pm\) 0.3 WT; \(n = 17\); \(N = 4\); \(P < 0.05\)) and DADs (10.75 \(\pm\) 3.08 TG vs. 3.63 \(\pm\) 1.32 WT; \(P < 0.05\)) were significantly increased in TRPC3-TG myocytes. Statistical significance analysed by Wilcoxon-Mann-Whitney test. (C) Incidence of afterdepolarizations (AD, left), delayed ADs (DAD, centre), and early ADs (EAD, right): WT compared with TRPC3-TG cells \(\pm\) Ca\textsuperscript{2+} buffered to diastolic levels by 11 mM EGTA (\(n = 10\); \(N = 3\)) or in the presence of the NCX1 inhibitor DCB (10 \(\mu\)M; \(n = 8\); \(N = 3\)). Black bars represent population of cells displaying arrhythmic events during 10 min (\(n > 3\)). * indicates statistical significance \((P < 0.05)\) in comparison to WT conditions, sharp (#) indicates \((P < 0.05)\) in comparison to untreated TRPC3-TG myocytes. Statistical significance analysed by Fisher’s exact test.
in the presence of GSK. In WT myocytes, GSK promoted NCX currents only slightly to a level observed constitutively in TRPC3-TG myocytes. Thus, activation of TRPC3 at elevated expression levels significantly enhanced NCX currents in this voltage-clamp protocol, indicating that TRPC3 may dynamically affect ion concentration at the exchanger. Local, TRPC3-mediated Na\(^{+}\) loading at rest (holding potential) is expected to promote reverse-mode currents upon depolarization. The resulting Ca\(^{2+}\) accumulation during depolarization is, in turn, likely to facilitate Ca\(^{2+}\)-induced Ca\(^{2+}\) release and drive forward-mode currents upon subsequent repolarization. We hypothesized that these alterations in Ca\(^{2+}\) cycling may promote spontaneous Ca\(^{2+}\) mobilization from the SR representing a potential trigger of arrhythmic events.

We tested this concept by Ca\(^{2+}\) imaging experiments using confocal line scanning fluorescence microscopy. Ca\(^{2+}\) mobilization was visualized during a short subsequent, quiescent period in the absence of transmembrane Ca\(^{2+}\) and Na\(^{+}\) fluxes after an equilibrating train of stimuli in physiologic conditions as illustrated in Supplementary material online, Figure S8. Ca\(^{2+}\) spark frequency was significantly higher in TRPC3-TG than in WT myocytes already at basal levels of TRPC activity (Figure 5). Activation of TRPC3 by GSK (1 \(\mu\)M) clearly increased the frequency of Ca\(^{2+}\) sparks in TRPC3-TG and promoted Ca\(^{2+}\) discharge in WT myocytes to a level slightly below that observed in unstimulated TRPC3-TG myocytes. Interestingly, experiments designed to evaluate SR Ca\(^{2+}\) content did not indicate differences between TRPC3-TG and WT myocytes.

**Figure 4** Cardiac TRPC3 activity modulates NCX function. NCX currents were recorded by applying depolarizing voltage steps (500 ms) from a holding potential of -40 mV and quantified as the Ni\(^{2+}\)-sensitive current components at the end of the 500 ms depolarization steps (NCX reverse mode) and 20 ms after repolarization to -40 mV (forward mode). \(^{34,35}\) (A) Representative Ni\(^{2+}\)-sensitive outward currents recorded during depolarizing steps as well as subsequent tail currents upon repolarization to -40 mV for 4.5 s are shown for WT cardiomyocytes (left) and TG cardiomyocytes (right) in the absence \([n = 8; N = 3 (WT); n = 9; N = 3 (TG)]\) (top) and presence (bottom) of 1 \(\mu\)M GSK \([n = 8; N = 3 (WT); n = 12; N = 3 (TG)]\); SR function was eliminated by thapsigargin (3 \(\mu\)M) and L-type Ca\(^{2+}\) channels were blocked by nitrendipine (10 \(\mu\)M). (B) Mean \((\pm \text{SEM})\) I/V plots of Ni\(^{2+}\)-sensitive peak currents. Left: tail inward currents representing NCX forward-mode activity in WT and TRPC3-TG cells and in the absence or presence of 1 \(\mu\)M GSK. Tail currents represent Ni\(^{2+}\)-sensitive peak inward currents at 20 ms after repolarization to -40 mV with steady-state holding current subtracted. Right: mean \((\pm \text{SEM})\) peak outward currents recorded from WT and TRPC3-TG cells in the presence and absence of 1 \(\mu\)M GSK. * indicates significant difference \((P < 0.05)\) to WT, WT + GSK, and TRPC3-TG; sharp (#) significant difference \((P < 0.05)\) to WT + GSK cells. Statistical significance analysed by two-way Anova followed by Tukey’s post hoc tests.
Ca²⁺ myocytes are given in the supplemental information section (21,38) and is considered prerequisite for functional investigation of the proteins in cardiac myocytes. Additional dynamic changes in the TRPC3-NCX crosstalk and set out course compared with that of current activation, we speculated about consequences of cardiac TRPC3 activation. We hypothesized that TRPC3 and NCX1 in TRPC3-TG myocytes by immunocytochemistry. TRPC3 and NCX1 were analysed and displayed significant FRET signals at resting conditions, indicative of direct coupling between the molecules (Figure 6D).

As TRPC3 activation was found to promote both NCX currents and Ca²⁺ mobilization from the SR with a considerably prolonged time course compared with that of current activation, we speculated about additional dynamic changes in the TRPC3-NCX crosstalk and set out to investigate localization of the proteins in cardiac myocytes. A close spatial relation between TRPC3 and NCX1 has previously been demonstrated (20,38) and considered prerequisite for functional consequences of cardiac TRPC3 activation. We hypothesized that alterations in spatial coupling between TRPC3 and NCX1 may be involved in prolongation of functional consequences of TRPC3 activation. In a first set of experiments, we analysed the localization of TRPC3 and NCX1 in TRPC3-TG myocytes by immunocytochemistry (Figure 6). Our results corroborated co-localization of the two transport molecules at basal conditions. Interestingly, activation of TRPC3 channels by GSK effectively disrupted co-localization of the signalling proteins (Figure 6) and a similar effect was initiated by AngII (see Supplementary material online, Figure S9).

To more directly monitor the disruption of TRPC3-NCX complexes by GSK in cardiac cells, we performed FRET experiments in HL-1 murine atrial myocytes transfected to express fluorescent fusions of NCX1 and TRPC3. Cells expressing equal levels of the fluorescent proteins in the plasma membrane were analysed and displayed significant FRET signals at resting conditions, indicative of direct coupling between the molecules (Figure 6D).

Upon exposure to 1 μM GSK, FRET signal abruptly declined to a significantly lower level (Figure 6E), substantiating re-localization and dissociation of the molecules after activation of the channel with GSK.

It is tempting to speculate that rapid spatial uncoupling of TRPC3 from NCX will lower local Na⁺ at the exchange during repolarization, which is expected to impact differentially on reverse and forward-mode operation of NCX, promoting preferentially forward-mode Na⁺ entry. Our results clearly suggest activity-dependent coupling between cardiac TRPC3 and NCX1 (Figure 7) as a potential mechanism for tuning of TRPC3/NCX1-mediated control of cardiac Ca²⁺ homeostasis, contractility, and excitability.

4. Discussion

Using a murine model of cardiac TRPC3 overexpression and a novel pharmacological tool to directly activate TRPC3 channels, we obtained...
evidence for a Ca$^{2+}$-dependent impact of a non-selective TRPC conductance on cardiac functions. We demonstrate that acute activation of cardiac TRPC3 increases contractility and promotes arrhythmias by a process most likely involving TRPC3/NCX1 interaction. Lipid-regulated TRPC channels are suggested to form a signalling complex with NCX1, which contribute to adaptation of cardiac contractility during remodelling processes and represent a potential player in arrhythmogenesis.

4.1 TRPC3 expression and activity determines cardiac contractility and rhythm

Although a pivotal role of lipid-regulated TRPC channels in cardiac hypertrophic remodelling has repeatedly been demonstrated, their impact on contractility and excitability of the heart is still elusive. Judgment of the role of cardiac TRPC channels is generally hampered by high variability of expression levels and by the fact that activation of TRPC conductances by (patho)physiological stimuli is inevitably associated with parallel changes in phospholipid and Ca$^{2+}$ signalling, which make clear assignment of functional changes to a TRPC conductance difficult. Understanding of the exact link between TRPC activity and cardiac function is prerequisite for development of pharmacological strategies based on TRPC as target structure. In this study, we took advantage of a model of cardiac-specific overexpression of TRPC3 and the availability of a novel small molecule activator of TRPC3 channels. As TRPC3 expression is essentially low in wild-type mice, the organ-specific overexpression model allowed for evaluation of TRPC3 selectivity of the novel activator GSK. The synthetic TRPC3 agonist initiated a

Figure 6  GSK disrupts TRPC3 and NCX colocalization in adult mouse cardiomyocytes. (A) Confocal fluorescence images of freshly isolated cardiac myocytes (N = 3) without (top) and after 5-min exposure to GSK (bottom) and stained for NCX1 (FITC, green) and TRPC3 (TRITC, red) were obtained using a Leica SP5 confocal microscope (Leica Microsystems, Mannheim, Germany). Immunostaining was performed as described previously. Magnified parts of the images depicting cell regions used for line scan analysis shown in B. (B) Overlap of FITC-NCX and TRITC-TRPC3 fluorescence intensities along a line scan (white line in micrograph) in the absence (top) and after 5-min exposure to GSK (bottom). Well-correlated intensity peaks are indicated by arrows, non-correlating peaks by X. (C) Mean (±SEM) pearson correlation coefficients (left) and non-linear correlation coefficients (right) of FITC-NCX and TRITC-TRPC3 fluorescence intensity as gained from line scans (n = 6) recorded in myocytes with and without exposure to 1 µM GSK as indicated. (D) Fluorescence microscopic images of HL-1 cells transfected with CFP-NCX split exchanger (CFP-NCX-265 + NCX-272, cyan), YFP-TRPC3 (green), overlay of YFP-TRPC3, and CFP-NCX split exchanger fluorescence (overlay) and net FRET after bleedthrough- and colocalization correction (nFRET) as described in Ref. 39. (E) Representative time course of rawFRET intensity recorded from a cell expressing YFP-TRPC3 and CFP-NCX-265 + NCX-272 (background subtracted), Image showing non-normalized FRET (rawFRET) recorded at the initial phase of the timeline. After 1 min, 1 µM GSK was added to the chamber. Insert showing mean normalized rawFRET intensities (±SEM) recorded at indicated times from six independent experiments. Statistical significance was analysed by t-test.
conductance with classical TRPC3 features in a strictly TRPC3 expression-dependent manner, indicating selective activation of TRPC3 channels. Consistently, other cardiac conductances or action potential parameters were barely affected by GSK. Although TRPC3 expression in healthy wild-type mice is low, the cation channel is typically up-regulated during maladaptive cardiac remodelling. Thus, the here deployed overexpression model allows for a specific analysis of the functional consequences of TRPC3 up-regulation in the heart. Previous studies questioned an impact of TRPC channels on cardiac excitation–contraction coupling based on a lack of TRPC localization in diade structures and proximity to L-type Ca$^{2+}$ channels. Here we demonstrate a transient increase in contractility, associated with arrhythmogenesis as an acute response to direct TRPC3 channel activation. Elevated expression of TRPC3 has previously been reported to lack significant effects on contractility in basal conditions or to even reduce contractility in the absence of TRPC3-activating stimuli using post rest stimulation protocols. The latter effect was observed in feline myocytes and was attributed to TRPC-induced promotion of Ca$^{2+}$ leakage by TRPC3. Importantly, our results show that TRPC3 expression promotes Ca$^{2+}$ turnover, as evident from enhanced release of Ca$^{2+}$ from the SR at preserved filling, even in the absence of activating stimuli. This suggests that overexpression of the channel protein, which has previously been demonstrated to display constitutive activity, affects cardiac Ca$^{2+}$ homeostasis without detectable alterations in cardiac function. Nonetheless, activation of the channel by either the synthetic agonist GSK or the (patho)physiological activator AngII resulted in a transiently increased TRPC conductance that apparently triggered positive inotropy and arrhythmias. This is in principle consistent with general biophysical considerations regarding the impact of a non-selective cation conductance on resting membrane potential, action potential shape, and Ca$^{2+}$ homeostasis.

**Figure 7** Hypothetical model of dynamic, functional interaction between TRPC3 and NCX1. TRPC3-mediated inotropy (upper left) requires close spatial proximity to NCX1. Cytoplasmic Ca$^{2+}$ concentration is elevated by (i) suppressed intracellular Ca$^{2+}$ clearance through NCX1 and (ii) by the TRPC3 Ca$^{2+}$ conductance itself. NCX forward-mode Ca$^{2+}$ extrusion is limited to negative potentials, leading to enhanced Ca$^{2+}$ loading of the SR. Excessive activation of TRPC3 results in transient Ca$^{2+}$ overload followed by both channel inactivation and rapid spatial uncoupling from NCX1. While SR loading slowly declines, rapid drop in local cytoplasmic Na$^+$ at the exchanger is expected to transiently favour arrhythmogenesis by facilitation of NCX forward mode (upper right).
channel activity by GSK or AngII remained unchanged, while effects on action potential waveform and arrhythmogenesis were profoundly suppressed. These results suggest that TRPC3 determines arrhythmogenesis not primarily by generation of a non-selective conductance but by a complex modulation of Ca\textsuperscript{2+} homeostasis and Ca\textsuperscript{2+}-dependent excitability. As TRPC conductances are considered to affect sub-plasmalemmal Na\textsuperscript{+} and Ca\textsuperscript{2+} levels, we hypothesized an impact of TRPC3 on NCX operation as the basis of the observed changes in excitability.

4.2 Communication between cardiac TRPC3 and NCX1 determines action potential morphology

A signalling partnership between lipid-sensitive TRPC isoforms and NCX1 has previously been suggested for different cardiovascular cell types.\textsuperscript{21,22,23} Our results obtained in mouse ventricular myocardium corroborated this concept. Three lines of evidence suggest that TRPC3-NCX1 communication mediates functional consequences of TRPC3 activation in the heart: (i) TRPC3 and NCX1 showed significant colocalization in cardiomyocytes. (ii) Action potential prolongation and arrhythmic activity were suppressed by intracellular EGTA without significant suppression of the TRPC3 conductance. (iii) The NCX1 inhibitor DCB effectively inhibited both action potential prolongation and arrhythmias. Overall, these effects are consistent with an involvement of NCX in GSK-induced arrhythmic events. Nonetheless, it is of note that inhibition by DCB on its own is certainly insufficient to conclude NCX involvement due to limited selectivity of this pharmacological tool. TRPC conductances have been proposed to affect NCX operation by elevation of Na\textsuperscript{+} cellular levels, thereby reducing Ca\textsuperscript{2+} extrusion or even promote Ca\textsuperscript{2+} entry at positive potentials.\textsuperscript{21,33} Similar to glycoside inhibitors of K\textsuperscript{-}/Na\textsuperscript{+} ATPase, elevated TRPC3 expression is expected to perturb Ca\textsuperscript{2+} extrusion by NCX1 due to elevation of local Na\textsuperscript{+} at the exchanger. We therefore hypothesized that TRPC3 channel activity increases cellular Ca\textsuperscript{2+} by mediating combined Ca\textsuperscript{2+} and Na\textsuperscript{+} entry at NCX1 to generate a cardiac glycoside-like effect.\textsuperscript{38,42} as illustrated in the hypothetical scheme shown in Figure 7. This concept was supported by our observation that TRPC3 overexpression, already at basal levels of channel activity, significantly enhanced discharge of Ca\textsuperscript{2+} from the SR. This effect was further accentuated during activation of channels with GSK and is most likely based not only on Ca\textsuperscript{2+} entering through TRPC3 channels but on reduced Ca\textsuperscript{2+} extrusion or even reverse-mode Ca\textsuperscript{2+} entry at positive potentials (Figure 7). Consistently, we observed TRPC3-dependent promotion of cyclic NCX activity in a voltage-clamp protocol (Figure 4), corroborating the principle of a rather direct modulation of NCX operation by the TRPC3 conductance. Enhanced reverse-mode currents during strong depolarizing pulses were followed by exaggerated forward-mode operation during subsequent hyperpolarization of TRPC3-overexpressing myocytes. It appears conceivable that activation of a Na\textsuperscript{+} permeable channel in proximity of NCX1 generates a gain in the dynamic function of the exchanger as previously suggested for Na\textsuperscript{+}V channels.\textsuperscript{41} Although reverse-mode NCX-mediated Ca\textsuperscript{2+} entry may be limited during the short murine action potential, TRPC3 is expected to profoundly elevate local Na\textsuperscript{+} as well as Ca\textsuperscript{2+} at NCX at negative potentials and thereby promote Na\textsuperscript{+} accumulation during depolarizations. Our results unequivocally demonstrate such tight communication between the two cardiac transport molecules. Nonetheless, local communication between NCX and TRPC3 does not explain the time course of arrhythmic events, which clearly outlasted TRPC3 current activation. However, we identified an additional mechanism that may contribute to TRPC3-mediated arrhythmogenesis. Our analysis of subcellular localization of TRPC3 and NCX1 by immunocytochemistry as well as of fluorescent fusion proteins expressed in HL-1 atrial myocytes confirmed colocalization and physical interaction. Importantly, our experiments revealed activity-dependent disruption of local coupling between the TRPC channel and the exchanger. This phenomenon was initiated by channel activation, develops within 2–10 min after agonist stimulation, and is suggested to facilitate NCX-inward currents due to a drop in local Na\textsuperscript{+} at the exchanger. Rapid reduction of Na\textsuperscript{+} entry into a sub-plasmalemmal space of restricted diffusion is expected to affect NCX function during action potentials and to promote late EADs or DADs. This effect may in part involve removal of Na\textsuperscript{+}-dependent inhibition of NCX.\textsuperscript{44,45}

It is thus tempting to speculate that this scenario is the basis of transient facilitation of arrhythmogenesis (see scheme in Figure 7). We suggest a model of cardiac TRPC3-NCX interaction in which NCX function is determined by proximity to TRPC3. At basal levels of TRPC3 activity and spatial coupling between the signalling molecules within a nano/ microdomain, NCX forward mode is limited by local Na\textsuperscript{+} entry. Along with TRPC3-mediated Ca\textsuperscript{2+} entry, this state is proposed to account for enhanced Ca\textsuperscript{2+} mobilization from the SR and positive inotropy during channel activation. Abrupt dissociation of TRPC3 from NCX may promote arrhythmic events.

4.3 TRPC3-NCX signalplexes as potential therapeutic targets in the myocardium

Lipid-sensitive TRPC3/6/7 channels have recently emerged as potential therapeutic targets for the prevention of cardiac remodelling. Early stages of hypertrophic remodelling have been characterized by enhanced expression of lipid-sensitive TRPC channel complexes,\textsuperscript{15} and Ca\textsuperscript{2+} entry via these channels has clearly been identified as a signal that triggers Ca\textsuperscript{2+}-dependent expression of prohypertrophic genes.\textsuperscript{12} Therefore, TRPC channels are proposed as elements of a critical feed-forward process in pathological remodelling, and inhibition of these channels might be considered as a strategy for prevention of heart failure development. It is important to point out that our results were obtained with a murine model of cardiac dysfunction. As this experimental model represents a specific type of cardiac muscle with Ca\textsuperscript{2+} handling being different from that in larger rodents or humans, conclusions to human pathology need to be drawn with care. Nevertheless, our current study employing a TRPC3 overexpression model unravels TRPC3 expression as a potential determinant of contractile function and susceptibility to arrhythmic stimuli. A recent report attributed the role of cardiac TRPC3 in arrhythmogenesis to the channel’s expression in fibroblasts.\textsuperscript{46} Here we present evidence that enhanced levels of TRPC3 in cardiomyocytes modify promote arrhythmogenic effects of AngII, which is known to evoke similar electrophysiological effects as GSK in the TRPC3-overexpressing heart. Enhanced cardiac expression of TRPC3 might be beneficial to restore contractility in early stages of remodelling. Excessive activation of the lipid-sensitive cation channels is, however, associated with enhanced arrhythmogenesis and Ca\textsuperscript{2+}- overload-mediated cardiac dysfunction. This concept opens the view on novel therapeutic strategies based on targeting specific TRPC3 functions or its molecular coupling to NCX1.

Supplementary material

Supplementary material is available at Cardiovascular Research online.
Acknowledgements
The authors thank J. Molkentin for providing the TRPC3 transgenic mouse line and K. Phillipson and J. Scott for providing NCX fusion constructs.

Conflict of interest: none declared.

Funding
This work was supported by FWF grants P21925-B19 to K.G. and DK+ Metabolic and Cardiovascular Disease, grant W2126-B18. Funding to pay the Open Access publication charges for this article was provided by FWF grant W2126.

References
1. Onohara N, Nishida M, Inoue R, Kobayashi H, Sumimoto H, Sato Y, Mori Y, Nagao T, Kurose H. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J 2006;25:3053–5136.
2. Zhu W, Zhou Y, Shirouma I, Kudoh S, Akita R, Hayashi D, Mizukami M, Toku H, Shibasaki F, Yazaki Y, Naga R, Komuro I. Ca2+ /calmodulin-dependent kinase II and calcinium play critical roles in endothelin-1-induced cardiac hypertrophy. J Biol Chem 2007;282:1239–15245.
3. Liu N, Gong K-Z, Cai Y-B, Li Z. Identification of proteins responding to adrenergic receptor stimulation in HL-1 myocytes. J Mol Cell Cardiol 2010;48:81–89.
4. Goonasekera SA, Molkentin JD. Unraveling the secrets of a double life: contractile versus electric function in cardiac myocytes. Biochem Mol Biol 2011;76:1140–1146.
5. Shirai-Tani N, Folgering JHA, Bichet D, Duprat F, Delmas P, Patel A, Honoré E. Sensing pressure in the cardiovascular system: Gq-coupled mechanoreceptors and TRP channels. J Mol Cell Cardiol 2010;48:81–89.
6. Goonasekera SA, Molkentin JD. Phospholipase C-dependent control of cardiac calcium homeostasis in vivo. Proc Natl Acad Sci USA. 2007;104:1140–1146.
7. Venetucci LA, Trafford AW, O’Neil SC, Eisner DA. Na+/Ca2+ exchange: regulator of intracellular calcium and source of arrhythmias in the heart. Ann NY Acad Sci 2007;1099:315–325.
8. Hohendanner F, Ljubojevic S, Macquaide N, Sacherer M, Sedej S, Biesmans L, Wakula P, Adam-Mikael S, Ropers HMH, Farman M. Allostery of the transmembrane helix 5 (TM5) of TRPC3 reveals allosteric coupling between gate and selectivity filter. A novel homology model of TRPC3 reveals allosteric coupling between gate and selectivity filter. J Biol Chem 2011;286:19146–19150.
9. Hohendanner F, Ljubojevic S, Macquaide N, Sacherer M, Sedej S, Biesmans L, Wakula P, Adam-Mikael S, Ropers HMH, Farman M. Allostery of the transmembrane helix 5 (TM5) of TRPC3 reveals allosteric coupling between gate and selectivity filter. A novel homology model of TRPC3 reveals allosteric coupling between gate and selectivity filter. J Biol Chem 2011;286:19146–19150.
10. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. Role of the sarco(endoplasmic reticulum Ca2+/CaM ATPase in the pathogenesis of cardiac hypertrophy. Circ Res 2000;87:774–780.
11. Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek P, Richardson JA, van Breemen C. Transient receptor potential canonical-3 channel antagonist inhibits hypertrophic growth in HL-1 myocytes. Circulation 2007;116:1660–1670.
12. Poteser M, Schleifer H, Platzter D, Romanin C, Groschner K. Phospholipase C-dependent control of cardiac calcium homeostasis involves a TRPC3-NCX1 signaling complex. Cardiovasc Res 2007;73:111–119.
13. Poburko D, Zhao C-H, Lemos VS, Lin E, Maruyama Y, Cole WC, van Breeven C. Transient receptor potential channel 6-mediated, localized cytosolic [Na+] transients drive Na+/Ca2+ -exchanger driven Ca2+ entry in purinergically stimulated aorta smooth muscle cells. Circ Res 2007;101:1030–1038.
14. Escobar M, Cardenas C, Colavita K, Petrenko NB, Franzini-Armstrong C. Structural evidence for perinuclear calcium microdomains in cardiac myocytes. Circ Res 2006;100:1097–1102.
15. Lifante J, Sáez de Miera E, Ferrer J, Rodríguez S, Molkentin JD, Eder P. Role of transient receptor potential canonical-3 channels in cardiac myocytes. Circ Res 2011;109:1441–1446.
16. Lines GT, Sande JB, Louch WE, Mørk HK, Grøttum P, Sejersted OM. Contribution of the angiotensin II-(AT1)-dependent transgenic model to hypertrophy. J Mol Cell Cardiol 2011;43:1846–1850.
17. Poburko D, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy. Curr Protoc Protein Sci 2009;56:1.5.1–1.5.12.
18. Eder P, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy. Circ Res 2011;108:265–272.
19. Dietrich, A. Maders y Schnitzler M, Emme J, Falke LA, Molkentin JD, Eder P. A novel link between Na+/Ca2+ exchange and local coupling to the Na+/Ca2+ exchange inhibitor, BAY 15-7532, high level of Na+/Ca2+ exchange activity in murine ventricular cardiomyocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation 2000;101:2137–2144.
20. Hohendanner F, Ljubojevic S, Macquaide N, Sacherer M, Sedej S, Biesmans L, Wakula P, Adam-Mikael S, Ropers HMH, Farman M. Allostery of the transmembrane helix 5 (TM5) of TRPC3 reveals allosteric coupling between gate and selectivity filter. A novel homology model of TRPC3 reveals allosteric coupling between gate and selectivity filter. J Biol Chem 2011;286:19146–19150.
21. Brunsner F, Andrew P, Wolkert G, Zeichen R, Mayer B. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 2001;104:3079–3102.
22. Brenner JS, Dolmetsch RE. TrpC3 regulates hypertrophy-associated gene expression in adipose triglyceride lipase deficiency: treatment with a PPARα agonist. Br J Pharmacol 2011;165:385–389.
23. Poburko D, Molkentin JD, Eder P. Role of transient receptor potential canonical-3 channels in cardiac myocytes. Circ Res 2011;109:1441–1446.
24. Brunner F, Andrew P, Wolkart G, Zeichen R, Mayer B. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 2001;104:3079–3102.
25. Lubec G, Bottazzo G, Maggini M, Loria M, Loew M, Bestetti A, Caidahl K. Contribution of the angiotensin II-(AT1)-dependent transgenic model to hypertrophy. J Mol Cell Cardiol 2011;43:1846–1850.
26. Sadee S, Heinzel FR, Walther S, Dybkova N, Wakuła P, Grabrot J, Grenau P, Maier LS, Vos MA, Laia FA, Napolitano C, Prongi SG, Kockskamper J, Pieske B. Na+ /Ca2+ -dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovasc Res 2010;87:50–59.
27. Blaucht K, Berd DS. Sarcoplasmic reticulum Ca2+ release causes myocyte depolarization: underlying mechanism and threshold for triggered action potentials. Circ Res 2000;87:657–667.
28. Shibasaki F, Yazaki Y, Nagai R, Komuro I. Ca2+ /calmodulin-dependent kinase II and calcium play critical roles in endothelin-1-induced cardiac hypertrophy. J Biol Chem 2007;282:1239–15245.
29. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
30. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
31. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
32. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
33. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
34. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
35. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
36. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
37. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
38. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
39. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.
40. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release mediates contraction. Circ Res 1998;83:251–258.